Taysha Gene Therapies, Inc. company insiders have only been selling lately: three insiders sold about $6.7 million of stock over 12 months, with no open-market purchases.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
5 quarters in a row of net selling by insiders. Insiders bought in 1 of the last 7 full quarters. On the institutional side, 209 funds reported holding TSHA at the end of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Nagendran Sukumar | President | Sell | 200,000 | $6.24 | $1.2M | SEC |
| Apr 13, 2026 | Nagendran Sukumar | President | Sell | 200,000 | $4.46 | $892K | SEC |
| Feb 6, 2026 | Alam Kamran | CFO | Sell | 1,655 | $4.52 | $7K | SEC |
| Jan 27, 2026 | Nagendran Sukumar | President | Sell | 89,132 | $4.75 | $423K | SEC |
| Jan 27, 2026 | Nagendran Sukumar | President | Sell | 26,918 | $4.61 | $124K | SEC |
| Jan 27, 2026 | Nolan Sean P. | CEO | Sell | 41,312 | $4.61 | $190K | SEC |
| Jan 27, 2026 | Nolan Sean P. | CEO | Sell | 136,789 | $4.75 | $650K | SEC |
| Jan 27, 2026 | Alam Kamran | CFO | Sell | 78,968 | $4.75 | $375K | SEC |
| Jan 27, 2026 | Alam Kamran | CFO | Sell | 23,849 | $4.61 | $110K | SEC |
| Jan 14, 2026 | Nagendran Sukumar | President | Sell | 200,000 | $4.71 | $942K | SEC |
| Dec 1, 2025 | Nagendran Sukumar | President | Sell | 110,125 | $4.75 | $523K | SEC |
| Dec 1, 2025 | Nagendran Sukumar | President | Sell | 260,047 | $4.51 | $1.2M | SEC |
| Sep 12, 2025 | Nagendran Sukumar | President | Sell | 200,000 | $3.23 | $646K | SEC |
| Aug 22, 2025 | Nagendran Sukumar | President | Sell | 57,054 | $2.85 | $163K | SEC |
| Aug 22, 2025 | Alam Kamran | CFO | Sell | 54,491 | $2.85 | $155K | SEC |
In the last 12 months Taysha Gene Therapies, Inc. insiders made open-market purchases worth about $0 and sales worth about $6.7 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in TSHA was filed on 2026-07-10.
209 investment managers reported holding TSHA in SEC Form 13F filings for Q2 2026.
No congressional trades in TSHA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).